Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free OBLN Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

Obalon Therapeutics (OBLN) Competitors

Obalon Therapeutics logo
Compare

OBLN vs. NSPR, HSAQ, TMDIF, PETV, and RVP

Should you be buying Obalon Therapeutics stock or one of its competitors? The main competitors of Obalon Therapeutics include InspireMD (NSPR), Health Sciences Acquisitions Co. 2 (HSAQ), Titan Medical (TMDIF), PetVivo (PETV), and Retractable Technologies (RVP). These companies are all part of the "medical" sector.

How does Obalon Therapeutics compare to InspireMD?

InspireMD (NYSE:NSPR) and Obalon Therapeutics (NASDAQ:OBLN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

InspireMD has a net margin of -413.96% compared to Obalon Therapeutics' net margin of -776.76%. InspireMD's return on equity of -69.42% beat Obalon Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
InspireMD-413.96% -69.42% -57.68%
Obalon Therapeutics -776.76%-161.38%-83.58%

Obalon Therapeutics has lower revenue, but higher earnings than InspireMD.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InspireMD$10.85M5.01-$19.92M-$0.73N/A
Obalon Therapeutics$1.59M13.43-$12.33MN/AN/A

InspireMD presently has a consensus target price of $4.50, indicating a potential upside of 287.93%. Given InspireMD's stronger consensus rating and higher possible upside, analysts clearly believe InspireMD is more favorable than Obalon Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InspireMD
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Obalon Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

44.8% of InspireMD shares are owned by institutional investors. Comparatively, 18.6% of Obalon Therapeutics shares are owned by institutional investors. 34.1% of InspireMD shares are owned by insiders. Comparatively, 8.1% of Obalon Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, InspireMD had 12 more articles in the media than Obalon Therapeutics. MarketBeat recorded 12 mentions for InspireMD and 0 mentions for Obalon Therapeutics. InspireMD's average media sentiment score of 0.22 beat Obalon Therapeutics' score of 0.00 indicating that InspireMD is being referred to more favorably in the media.

Company Overall Sentiment
InspireMD Neutral
Obalon Therapeutics Neutral

InspireMD has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, Obalon Therapeutics has a beta of -1.23, meaning that its stock price is 223% less volatile than the S&P 500.

Summary

InspireMD beats Obalon Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Obalon Therapeutics compare to Health Sciences Acquisitions Co. 2?

Obalon Therapeutics (NASDAQ:OBLN) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

18.6% of Obalon Therapeutics shares are held by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. 8.1% of Obalon Therapeutics shares are held by insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Obalon Therapeutics' average media sentiment score of 0.00 equaled Health Sciences Acquisitions Co. 2'saverage media sentiment score.

Company Overall Sentiment
Obalon Therapeutics Neutral
Health Sciences Acquisitions Co. 2 Neutral

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than Obalon Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Obalon Therapeutics$1.59M13.43-$12.33MN/AN/A
Health Sciences Acquisitions Co. 2N/AN/A-$380KN/AN/A

Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to Obalon Therapeutics' net margin of -776.76%. Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat Obalon Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Obalon Therapeutics-776.76% -161.38% -83.58%
Health Sciences Acquisitions Co. 2 N/A N/A -2.38%

Obalon Therapeutics has a beta of -1.23, indicating that its stock price is 223% less volatile than the S&P 500. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, indicating that its stock price is 91% less volatile than the S&P 500.

Summary

Health Sciences Acquisitions Co. 2 beats Obalon Therapeutics on 7 of the 8 factors compared between the two stocks.

How does Obalon Therapeutics compare to Titan Medical?

Obalon Therapeutics (NASDAQ:OBLN) and Titan Medical (NASDAQ:TMDIF) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Titan Medical has higher revenue and earnings than Obalon Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Obalon Therapeutics$1.59M13.43-$12.33MN/AN/A
Titan Medical$17.63M1.84$6.95M$0.055.68

Titan Medical has a net margin of 0.00% compared to Obalon Therapeutics' net margin of -776.76%. Titan Medical's return on equity of -82.31% beat Obalon Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Obalon Therapeutics-776.76% -161.38% -83.58%
Titan Medical N/A -82.31%-51.47%

18.6% of Obalon Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of Titan Medical shares are owned by institutional investors. 8.1% of Obalon Therapeutics shares are owned by company insiders. Comparatively, 0.0% of Titan Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Obalon Therapeutics has a beta of -1.23, indicating that its stock price is 223% less volatile than the S&P 500. Comparatively, Titan Medical has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500.

In the previous week, Titan Medical had 1 more articles in the media than Obalon Therapeutics. MarketBeat recorded 1 mentions for Titan Medical and 0 mentions for Obalon Therapeutics. Obalon Therapeutics' average media sentiment score of 0.00 equaled Titan Medical'saverage media sentiment score.

Company Overall Sentiment
Obalon Therapeutics Neutral
Titan Medical Neutral

Summary

Titan Medical beats Obalon Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Obalon Therapeutics compare to PetVivo?

PetVivo (NASDAQ:PETV) and Obalon Therapeutics (NASDAQ:OBLN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

24.5% of PetVivo shares are owned by institutional investors. Comparatively, 18.6% of Obalon Therapeutics shares are owned by institutional investors. 10.8% of PetVivo shares are owned by insiders. Comparatively, 8.1% of Obalon Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, PetVivo's average media sentiment score of 0.00 equaled Obalon Therapeutics'average media sentiment score.

Company Overall Sentiment
PetVivo Neutral
Obalon Therapeutics Neutral

PetVivo has higher earnings, but lower revenue than Obalon Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PetVivo$1.05M26.75-$10.95M-$0.38N/A
Obalon Therapeutics$1.59M13.43-$12.33MN/AN/A

Obalon Therapeutics has a net margin of -776.76% compared to PetVivo's net margin of -902.82%. Obalon Therapeutics' return on equity of -161.38% beat PetVivo's return on equity.

Company Net Margins Return on Equity Return on Assets
PetVivo-902.82% -4,813.07% -281.78%
Obalon Therapeutics -776.76%-161.38%-83.58%

PetVivo has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500. Comparatively, Obalon Therapeutics has a beta of -1.23, meaning that its stock price is 223% less volatile than the S&P 500.

Summary

PetVivo and Obalon Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Obalon Therapeutics compare to Retractable Technologies?

Retractable Technologies (NYSE:RVP) and Obalon Therapeutics (NASDAQ:OBLN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

7.6% of Retractable Technologies shares are owned by institutional investors. Comparatively, 18.6% of Obalon Therapeutics shares are owned by institutional investors. 59.5% of Retractable Technologies shares are owned by company insiders. Comparatively, 8.1% of Obalon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Retractable Technologies had 1 more articles in the media than Obalon Therapeutics. MarketBeat recorded 1 mentions for Retractable Technologies and 0 mentions for Obalon Therapeutics. Retractable Technologies' average media sentiment score of 0.00 equaled Obalon Therapeutics'average media sentiment score.

Company Overall Sentiment
Retractable Technologies Neutral
Obalon Therapeutics Neutral

Retractable Technologies has higher revenue and earnings than Obalon Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Retractable Technologies$38.27M0.55-$7.01M-$0.42N/A
Obalon Therapeutics$1.59M13.43-$12.33MN/AN/A

Retractable Technologies has a net margin of -41.11% compared to Obalon Therapeutics' net margin of -776.76%. Retractable Technologies' return on equity of -17.15% beat Obalon Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Retractable Technologies-41.11% -17.15% -9.33%
Obalon Therapeutics -776.76%-161.38%-83.58%

Retractable Technologies has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. Comparatively, Obalon Therapeutics has a beta of -1.23, indicating that its stock price is 223% less volatile than the S&P 500.

Summary

Retractable Technologies beats Obalon Therapeutics on 9 of the 11 factors compared between the two stocks.

Get Obalon Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for OBLN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OBLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OBLN vs. The Competition

Export
MetricObalon TherapeuticsSurgical & Medical Instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$21.35M$47.77M$6.30B$12.15B
Dividend YieldN/A1.08%2.77%5.24%
P/E Ratio-1.5815.8728.7027.01
Price / Sales13.4330.28528.4777.57
Price / CashN/A18.8843.6254.08
Price / Book3.5514.539.876.89
Net Income-$12.33M-$20.10M$3.54B$333.00M

Obalon Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OBLN
Obalon Therapeutics
N/A$2.13
+0.9%		N/A+406.5%$21.35M$1.59MN/A2
NSPR
InspireMD
3.1179 of 5 stars		$1.16
-1.7%		$5.00
+331.0%		-54.0%$54.40M$8.98MN/A50
HSAQ
Health Sciences Acquisitions Co. 2
N/A$3.99
+5.0%		N/A+56.6%$44.74MN/AN/A4
TMDIF
Titan Medical
N/A$0.32
+13.7%		N/A+12.3%$36.97M$17.63MN/A50
PETV
PetVivo
N/A$0.78
-0.1%		N/A+26.7%$27.96M$1.05MN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:OBLN) was last updated on 5/7/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...
Weiss Ratings | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel